Science vs. Systems · №01
Ask why a medicine for a rare childhood condition doesn't exist, and you'll usually hear a story about the science. Often, that's not the real story.
For a whole class of pediatric therapies, the science is sound — sometimes finished. What's scarce is patients. Not because the need isn't real, but because there are so few children with the condition that no commercial sponsor can justify carrying it forward.
We call it the Orphan Asset.
Big science, small population
An orphan asset treats a genuine condition in real children — just very few of them. The disease is rare; the population is narrow. And the smaller the population, the harder the math: development costs about the same whether a therapy will reach a million patients or a thousand — but the return does not. So the asset stalls, orphaned not by its science, but by its size.
The system is working as designed
Nothing here is broken. Capital flows to the largest returns; portfolios concentrate where the numbers are biggest. Every decision is rational. And the rational, cumulative result is that the rarest pediatric conditions are left to a market that was never going to show up for them.
Too few patients to fund it — never too few to matter.
The answer
This is the first of the two reasons the PediaMed Institute exists. We're a 501(c)(3) built to carry the medicines the market can't — starting with the ones whose patient populations are simply too small to pay a sponsor back. Where the numbers can't justify it, the mission can. A rare disease is still a child's disease.
An orphan asset doesn't need a bigger market. It needs someone for whom the size of the market was never the point.
Bring us the orphan
If you're holding an orphan asset — sound science, real need, a patient population too small to ever attract a commercial sponsor — that's exactly what we exist to finish. Bring us the orphan.
The science is ready. The system isn't. That's exactly where we work.